Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 628-640
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.628
Figure 1 Numbers and percentages of the study patients who had responses to (n = 100) and failure of (n = 100) the 16 direct-acting antiviral regimens.
EBR: Elbasvir; GZR: Grazoprevir; PrOD: Paritaprevir-ritonavir-ombitasvir-dasabuvir; SIM: Simeprevir.
- Citation: Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol 2020; 12(9): 628-640
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/628.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.628